Role of Lugol solution before total thyroidectomy for Graves’ disease: randomized clinical trial
Open Access
- 2 August 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 111 (8)
Abstract
Background: Lugol solution is often administered to patients with Graves’ disease before surgery. The aim is to reduce thyroid vascularization and surgical morbidity, but its real effectiveness remains controversial. The present study was designed to evaluate the effects of preoperative Lugol solution on thyroid vascularization and surgical morbidity in patients with Graves’ disease undergoing total thyroidectomy. Methods: Fifty-six patients undergoing total thyroidectomy for Graves’ disease were randomly assigned to receive 7 days of Lugol treatment (Lugol+ group, 29) or no Lugol treatment (LS– group, 27) before surgery in this single-centre and single-blinded trial. Preoperative hormone and colour Doppler ultrasonographic data for assessing thyroid vascularization were collected 8 days before surgery (T0) and on the day of surgery (T1). The primary outcome was intraoperative and postoperative blood loss. Secondary outcomes included duration of surgery, thyroid function, morbidity, vascularization, and microvessel density at final pathology. Results: No differences in demographic, preoperative hormone or ultrasonographic data were found between LS+ and LS– groups at T0. At T1, free tri-iodothyronine (FT3) and free thyroxine (FT4) levels were significantly reduced compared with T0 values in the LS+ group, whereas no such variation was observed in the LS– group. No differences between T0 and T1 were found for ultrasonographic vascularization in either group, nor did the histological findings differ. There were no significant differences between the LS+ and LS– groups concerning intraoperative/postoperative blood loss (median 80 versus 94 ml respectively), duration of surgery (75 min in both groups) or postoperative morbidity. Conclusion: Lugol solution significantly reduces FT3 and FT4 levels in patients undergoing surgery for Graves’ disease, but does not decrease intraoperative/postoperative blood loss, thyroid vascularization, duration of surgery or postoperative morbidity. Registration number: NCT05784792 (https://www.clinicaltrials.gov).Keywords
This publication has 19 references indexed in Scilit:
- Definition and diagnosis of postsurgical hypoparathyroidism after thyroid surgery: meta-analysisBJS Open, 2022
- Effect of preoperative potassium iodide administration on Graves’ disease surgery: a propensity score analysisThe American Journal of Surgery, 2021
- Preoperative Potassium Iodide Treatment in Patients Undergoing Thyroidectomy for Graves' Disease-Perspective of a European High-Volume CenterWorld Journal of Surgery, 2020
- The American Association of Endocrine Surgeons Guidelines for the Definitive Surgical Management of Thyroid Disease in AdultsAnnals of Surgery, 2020
- Graves’ DiseaseNew England Journal of Medicine, 2016
- Management of Graves DiseaseJAMA, 2015
- Effectiveness and Mechanism of Preoperative Lugol Solution for Reducing Thyroid Blood Flow in Patients with Euthyroid Graves’ DiseaseWorld Journal of Surgery, 2015
- Importance ofin situpreservation of parathyroid glands during total thyroidectomyBritish Journal of Surgery, 2015
- The effects of acupuncture after thyroid surgery: A randomized, controlled trialSurgery, 2014
- Total thyroidectomy for Graves’ disease: Compliance with American Thyroid Association guidelines may not always be necessarySurgery, 2013